Viridian Therapeutics, Inc.\DE (VRDN) Cash from Investing Activities (2013 - 2026)

Viridian Therapeutics, Inc.\DE's Cash from Investing Activities history runs 14 years deep, the most recent figure standing at $77.3 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities fell 22.79% year-over-year to $77.3 million; the TTM figure through Mar 2026 stood at -$60.4 million (down 517.57% YoY), while the FY2025 annual figure was -$37.6 million, up 83.57% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $77.3 million, up from -$339.4 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $126.1 million in Q3 2025, with the low at -$339.4 million in Q4 2025.
• The 5-year median for Cash from Investing Activities is $14.0 million (2022), against an average of -$23.4 million.
• The sharpest annual moves came in 2022 and 2024: Cash from Investing Activities soared 582.31% in 2022, then plunged 975.93% in 2024.
• Viridian Therapeutics, Inc.\DE's Cash from Investing Activities stood at -$180.6 million in 2022, then advanced by 6.03% to -$169.7 million in 2023, then surged by 62.93% to -$62.9 million in 2024, then plunged by 439.49% to -$339.4 million in 2025, then jumped by 122.76% to $77.3 million in 2026.
• Business Quant data shows VRDN's Cash from Investing Activities at $77.3 million in Q1 2026, -$339.4 million in Q4 2025, and $126.1 million in Q3 2025.